CD93 and prostate adenocarcinoma: Conversely, CD93 expression was reduced in colon adenocarcinoma (COAD), kidney renal papillary cell carcinoma (KIRP), kidney chromophobe (KICH), adrenocortical carcinoma (ACC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS), breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), bladder urothelial carcinoma (BLCA), and thyroid carcinoma (THCA).